文献速递重症综合管理与镇静镇痛心脑血管急症消化、代谢与肾脏急症

脓毒症危重患者肌钙蛋白I测量及肌钙蛋白I升高后心血管管理方法的差异

Variation in Troponin I Measurement and the Cardiovascular Management Approach Following Elevated Troponin I Among Critically Ill Patients With Sepsis.
PubMed 文献 · Crit Care Explor · 2023-01-10
一句话结论脓毒症危重患者肌钙蛋白I测量及升高后心血管诊疗在各医院间差异极大,需前瞻性研究指导。

该观察性队列研究利用Premier Healthcare Database,纳入2016至2020年收入ICU的85,830例成人脓毒症患者,描述各医院在肌钙蛋白I测量及肌钙蛋白I升高后心血管诊断与治疗上的差异,以医院中位比值比量化。61.8%患者测量了肌钙蛋白I,医院间中位比值比5.30(95%CI 4.98-5.67);32.2%患者肌钙蛋白I升高,其后续诊疗比例从4.1%的心脏负荷试验到84.8%的连续测量不等,医院间中位比值比1.28至7.58。结论认为各医院实践差异大,与诊疗效率和实践不一致相符,需前瞻性研究指导。

要点

  • 85,830例成人脓毒症中61.8%测量了肌钙蛋白I,医院间中位比值比5.30(95%CI 4.98-5.67),测量与否高度取决于收治医院。
  • 27,665例(32.2%)肌钙蛋白I升高者中84.8%行连续测量、66.0%追踪至峰值、66.7%行超声心动图、4.1%行心脏负荷试验、6.6%行心导管检查。
  • 肌钙蛋白I升高后48.3%用抗血小板药、8.3%用治疗性抗凝、50.5%用β受体阻滞剂、38.1%用他汀。
  • 医院间心血管诊疗中位比值比从β受体阻滞剂1.28(95%CI 1.24-1.32)到治疗性抗凝7.58(95%CI 6.43-8.77)。
  • 作者认为需前瞻性研究指导脓毒症中肌钙蛋白I测量与心血管评估的知情方法。

适用人群与场景

  • 2016至2020年收入ICU的18岁以上成人脓毒症患者。

研究设计与关键结果

  • 观察性队列研究,使用Premier Healthcare Database,纳入85,830例成人脓毒症患者,以医院为中位比值比量化医院间差异。
  • 53,058例(61.8%)测量了肌钙蛋白I,医院间中位比值比5.30(95%CI 4.98-5.67)。
  • 27,665例(32.2%)肌钙蛋白I升高:84.8%连续测量、66.0%追踪至峰值、66.7%超声心动图、4.1%心脏负荷试验、6.6%心导管检查、48.3%抗血小板药、8.3%治疗性抗凝、50.5%β受体阻滞剂、38.1%他汀。
  • 医院间心血管诊疗中位比值比范围从β受体阻滞剂1.28(95%CI 1.24-1.32)到治疗性抗凝7.58(95%CI 6.43-8.77)。

证据类型、等级与局限

  • 证据类型:观察性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文结论认为各医院在肌钙蛋白I测量及升高后心血管诊疗上差异大,与诊疗实践和效率不一致相符;作者认为需前瞻性研究指导脓毒症中肌钙蛋白I测量与心血管评估的方法。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

UNLABELLED: Troponin I is frequently elevated in sepsis, but optimal clinical approaches to diagnosis and management of troponin I during sepsis are unclear.

OBJECTIVES: We aimed to describe the variation in troponin I measurement and the cardiovascular diagnostic and therapeutic approach to elevated troponin I among critically ill adults with sepsis.

DESIGN SETTING AND PARTICIPANTS: Observational cohort study of the hospital-level variation in serial troponin I measurement, trending troponin I to peak, echocardiography, cardiac stress test, cardiac catheterization, antiplatelet agents, therapeutic anticoagulation, beta-blockers, and statins quantified using hospital median odds ratios-the median odds of receiving an intervention at randomly selected higher versus lower rate hospitals-derived from multivariable-adjusted random-effects logistic regression models with hospital site as the random effect. The Premier Healthcare Database was used. Patients were adults aged greater than 18 years admitted to the ICU with sepsis from 2016 to 2020.

MAIN OUTCOMES AND MEASURES: The hospital-level median odds ratios of troponin I measurement as well as cardiovascular diagnostics and therapeutics.

RESULTS: Among 85,830 adults with sepsis, 53,058 (61.8%) had a troponin I measured, with a median odds ratio of troponin measurement across hospitals of 5.30 (95% CI, 4.98-5.67). Among 27,665 adults (32.2%) with sepsis and an elevated troponin I level, 84.8% had serial troponin I measurements, 66.0% had troponin trended to peak level, 66.7% had an echocardiogram, 4.1% had a cardiac stress test, 6.6% underwent cardiac catheterization, 48.3% received antiplatelet agents, 8.3% received therapeutic anticoagulation, 50.5% received beta-blockers, and 38.1% received statins. The median odds ratios between hospitals for cardiovascular diagnostics and therapeutics ranged from 1.28 (95% CI, 1.24-1.32) for use of beta-blockers to 7.58 (95% CI, 6.43-8.77) for use of therapeutic anticoagulation.

CONCLUSIONS AND RELEVANCE: Both troponin I measurement and the approach to an elevated troponin I among critically ill adults with sepsis varied widely across hospitals consistent with disparate practice and care efficiency. Prospective studies are needed to guide an informed approach to troponin I measurement and cardiovascular evaluation in sepsis.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Garcia MA, Bosch NA, Peltan ID, et al. Variation in Troponin I Measurement and the Cardiovascular Management Approach Following Elevated Troponin I Among Critically Ill Patients With Sepsis. Crit Care Explor. 2023. PMID: 36699250. doi:10.1097/CCE.0000000000000842

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。